4JUL

Exeter spinout raises GBP3m for epilepsy

2 min read

11:24UTC

Neuronostics, an Exeter University spinout, raised GBP3m for BioEP, an EEG-based epilepsy biomarker, co-led by Empirical Ventures and The FSE Group with an Innovate UK grant.

← Back to AI takes record 44% as UK equity shrinks Jump to analysis ↓

TechnologyDeveloping

Key takeaway

Neuronostics paired a specialist fund with an Innovate UK grant to raise in the shrinking spinout tier.

Neuronostics, a University of Exeter spinout, raised GBP3m for BioEP, a digital biomarker that reads routine EEG (electroencephalogram, a recording of the brain's electrical activity) to help diagnose epilepsy without waiting for a seizure ¹. Empirical Ventures, a UK health-specialist investor, and The FSE Group, a regional fund manager, co-led, with the British Business Bank, Ascension, QantX, New Wave and Bristol angels, blended with a GBP400k Innovate UK Investor Partnerships grant, a government co-investment programme.

The round sits in exactly the sub-GBP5m spinout tier the national tracker shows contracting sharply in 2025 . A specialist fund co-led it and Innovate UK grant money topped it up.

The Innovate UK grant matches private capital rather than replacing it, so GBP400k de-risks the private cheques around it, a different instrument from the VCT tax relief April's change cut. Blended public-grant-plus-equity rounds like this are how the thin end of the spinout pipeline is being held together one deal at a time.

Deep Analysis

In plain English

Neuronostics grew out of research at the University of Exeter. It has built BioEP, a tool that reads routine brain-wave recordings, known as EEGs, to help doctors diagnose epilepsy faster and without more invasive tests. The company raised £3m from two co-lead investors, plus a £400k top-up grant from Innovate UK, a government body that part-funds promising new British technology.

Source Landscape

This story draws on neutral-leaning sources

At £3m plus a £400k grant, Neuronostics' total funding of £3.4m is modest for a diagnostics platform that still needs clinical validation before wider NHS adoption, leaving little room for delay.

The grant covers roughly one-eighth of the round, which shows how thin Innovate UK's remaining early-stage funding pool has become relative to the private capital now doing most of the work that public grants used to carry alone.

Consensus view: The Wellcome Trust's health-innovation funding team sees blended structures like Neuronostics' £3m round, topped up with a £400k Innovate UK grant, becoming the default model for early health-tech spinouts as the retail angel base that used to fund them keeps shrinking .

Counter-view: Midlands Mindforge, the eight-university fund that wrote its first cheques in June , argues blended grant-equity financing is a stopgap: pooling several universities' capital directly into one larger regional fund still leaves an individual spinout better capitalised than a small private round patched together with a government top-up.

Key tension: Whether blended grant-and-equity financing is a durable long-term model for health-tech spinouts, or a patchwork response to a shrinking angel base that regional multi-university funds are better placed to fix.

Sources:UKTN

Mentions:Neuronostics →Radical Ventures →The FSE Group →British Business Bank →Innovate UK →Midlands Mindforge →Fudan University →

First Reported In

Update #10 · AI takes record 44% as UK equity shrinks

UKTN· 4 Jul 2026

Read original →

Causes and effects

This Event

Exeter spinout raises GBP3m for epilepsy

A blended specialist-fund and government-grant round shows the contracting spinout tier is thinner, not closed.

Led to

Five seed rounds stir beneath megadeals

Neuronostics' £3m epilepsy-biomarker round is part of the same thin, cross-sector seed tier this week's cluster extends.

Occurred 8 Jul 2026

Read story →

Different Perspectives

Institute of Physics

The Institute has long argued STFC's national-laboratory infrastructure, not its grant programmes, is the binding constraint on UK physics output, and warns mothballing capacity like Clara removes capability that cannot be rebuilt on a four-year cycle. It represents the discovery-science community absorbing the reallocation the Bank's equity cheques do not touch.

Helsing

The Munich-headquartered defence-AI firm chose Plymouth over Continental sites for a £350m manufacturing plant building underwater surveillance gliders, alongside its record raise. Its choice of postcode signals confidence in UK manufacturing capacity for defence hardware even as it looks abroad for the capital financing that hardware.

Dragoneer Investment Group, Lightspeed Venture Partners and Iconiq

The three US growth-capital firms backed Helsing's $1.8bn round at an $18bn valuation, more than doubling the mark set only a year earlier, with demand reportedly exceeding the capital on offer. Their money, not a UK sovereign vehicle, is what funds the Plymouth plant, extending a pattern of foreign capital underwriting British defence-hardware manufacturing this cycle.

British Business Bank

The Bank wrote its largest-ever direct life-sciences cheque into Alchemab and added a £6.5bn SME lending guarantee the same week UKRI confirmed the STFC cuts. It is deploying an April mandate change letting it lead venture rounds and invest directly up to £60m per company, treating equity extension rounds and small-business debt as newly within its risk appetite.

Daphni

The Paris seed fund joined Speedinvest and three UK backers in Astral Systems' GBP23m Series A for modular fusion reactors, one of the round's five European co-investors betting on lab-to-market fusion ahead of any working commercial reactor. Unlike CuspAI's all-foreign cap table, this round kept a UK lead investor in Mercia Ventures.

EQT

EQT, appointed by the European Innovation Council to run the EUR5bn Scaleup Europe Fund, entered advanced talks for a further CuspAI stake reported on 3 July, the fund's first pursuit of a UK-founded winner. A closed deal would put EU sovereign capital, not a UK vehicle, on the cap table of a company Britain's own funds passed over.